Management of Blood Cholesterol
Date Added:
February 5, 2019
Journal/Publication:
JAMA
Publisher:
American Medical Association
Publication Date:
February 4, 2019
DOI (1):
doi:10.1001/jama.2019.0015
Abstract
Pharmacologically lowering low-density lipoprotein cholesterol (LDL-C) consistently reduces ASCVD events (myocardial infarction, stroke, and cardiovascular death), and the principle that lower LDL-C is better was reaffirmed by trials that added ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy. The 2013 guideline removed specific LDL-C treatment targets, but high-quality trials since offered the opportunity to reintroduce such goals based on risk gradations.
RPR Commentary
This is an update to the 2013 blood cholesterol guidelines developed by the AHA, ACC and others. It re-adds LDL targets and the addition of cholesterol-lowering agents other than statins when necessary.